Advertisement

Quelle place pour la chirurgie en phase métastasique?

  • Éric Lechevallier
Chapter
  • 331 Downloads
Part of the Oncologie pratique book series (ONCOLPRAT)

Abstrait

Vingt à 30 % des cancers à cellules rénales (CCR) sont métastatiques au diagnostic et 20 à 40% des patients ayant eu une néphrectomie pour un CCR localisé vont développer des métastases (1). Le pronostic des CCR métastatiques est péjoratif avec une survie médiane de 6 à 10 mois et une survie à 2 ans de 10 à 20% (2).

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Références

  1. 1.
    Lam JS, Shvarts O, Leppert JT et al. (2005) Renal cell carcinoma 2005: new frontiers in staging, prognostication and targeted molecular therapy. J Urol 173: 1853–62PubMedCrossRefGoogle Scholar
  2. 2.
    Pantuck AJ, Belldegrun AS, Figlin RA (2007) Cytoreductive nephrectomy for metasttatic renal cell carcinoma: is it still imperative in the era of targeted therapy. Clin Cancer Res 13 (2 suppl): 693s–96sPubMedCrossRefGoogle Scholar
  3. 3.
    Flanigan RC, Salmon SE, Blummenstein BA et al. (2001) Nephrectomy followed by interferon a-2b compared with interferon a-2b alone for metastatic renal-cell cancer. N Engl J Med 345: 1655–9PubMedCrossRefGoogle Scholar
  4. 4.
    Mickisch GH, Garin A, van Poppel H et al. (2001) Radical nephrectomy plus interferon-a-based immunotherapy compared with interferon a alone in metastatic rena-cell carcinoma: a randomized trial. Lancet 1358: 966–70CrossRefGoogle Scholar
  5. 5.
    Motzer RJ, Mazumdar M, Bacik J et al. (1999) Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 17: 2530–40PubMedGoogle Scholar
  6. 6.
    Montie JE, Stewart BH, Straffon RA et al. (1977) The role of adjunctive nephrectomy in patients with metastatic renal cell carcinoma. J Urol 117: 272–5PubMedGoogle Scholar
  7. 7.
    Rini BI, Campbell SC (2007) The evolving role of surgery for advanced renal cell carcinoma in the era of molecular targeted therapy. J Urol 177: 1978–84PubMedCrossRefGoogle Scholar
  8. 8.
    Russo P, Snyder M, Vickers A et al. (2007) Cytoreductive nephrectomy and nephrectomy/complete metastasectomy for metastatic renal cancer. TSW Urology 2: 42–52CrossRefGoogle Scholar
  9. 9.
    Belldegrun A, Shvarts O, Figlin RA et al. (2000) Expanding the indications for surgery and adjuvant interleukin-2-based immunotherapy in patients with advanced renal cell carcinoma. Cancer J Sci Am 6: S88–92Google Scholar
  10. 10.
    Flanigan RC, Mickisch G, Sylvester R et al. (2004) Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol 171: 1071–6PubMedCrossRefGoogle Scholar
  11. 11.
    Han KR, Pantuck AJ, Bui MH et al. (2003) Number of metastatic sites rather than location dictates overall survival of patients with node negative metastatci renal-cell carcinoma. Urology 61: 314–9PubMedCrossRefGoogle Scholar
  12. 12.
    Pantuck AJ, Belldegrun AS, Figlin RA et al. (2001) Nephrectomy and interleukin-2 for metastatic renal-cell carcinoma. N Engl J Med 345: 1711–2PubMedCrossRefGoogle Scholar
  13. 13.
    Motzer RJ, Hutson TE, Tomczak P et al. (2007) Sunitinib versus inteferon alpha in metastatic renal cell carcinoma. N Engl J Med 356: 115–24PubMedCrossRefGoogle Scholar
  14. 14.
    Escudier B, Eisen T, Stadler WM et al. (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356: 125–34PubMedCrossRefGoogle Scholar
  15. 15.
    Motzer RJ, Russo P (2000) Systemic therapy for renal cell carcinoma. J Urol 163: 408–17PubMedCrossRefGoogle Scholar
  16. 16.
    Kavolius JP, Mastorakos DP, Pavlovich C et al. (1998) Resection of metastatic renal cell carcinoma. J Clin Oncol 16: 2261–66PubMedGoogle Scholar

Copyright information

© Springer-Verlag France, Paris 2008

Authors and Affiliations

  • Éric Lechevallier
    • 1
  1. 1.Service ďurologieHôpital SalvatorMarseilleFrance

Personalised recommendations